We have applied tegaful and uracil (UFT) treatment as adjuvant chemoth
erapy to patients after the completion of primary therapy. UFT was giv
en per os at a dose of 300 or 400 mg/day for more than 1 year. A retro
spective study was conducted on 15 patients, assessed as the UFT-treat
ed group, and 24 patients assessed as the UFT-nontreated group. The 5-
year survival rate in patients treated or not treated with UFT was 76.
6 and 22.6%, respectively. Among those who underwent surgery in combin
ation with other therapy, the 5-year survival rate was 74.1% with UFT
and 27.3% without UFT. In patients receiving chemotherapy plus radioth
erapy alone, the 5-year survival rate was 80.0% with UFT and 19.2% wit
hout UFT. In 23 patients with proven effects of neoadjuvant chemothera
py comprising 18 PR cases and 5 CR cases, a comparison was made betwee
n 10 patients treated with UFT and 13 patients not treated with UFT. A
s a result, the 5-year survival was 76.2 and 17.9%, respectively. In t
he patients with T3 disease, who occupied the majority, the 5-year sur
vival rate was 71.4 and 23.8%, respectively. Adjuvant chemotherapy wit
h UFT tends to show a substantial significant difference particularly
in patients who were successfully treated with radiotherapy plus chemo
therapy as the primary treatment. UFT was clearly shown to have a stat
istically significant effect, despite a small population. The findings
of the present investigation point to the value of conducting further
study to ascertain the effect of UFT by a randomized trial in a large
r population.